1. Home
  2. SSII vs ZYME Comparison

SSII vs ZYME Comparison

Compare SSII & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSII
  • ZYME
  • Stock Information
  • Founded
  • SSII N/A
  • ZYME 2003
  • Country
  • SSII India
  • ZYME United States
  • Employees
  • SSII N/A
  • ZYME N/A
  • Industry
  • SSII
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • SSII
  • ZYME Health Care
  • Exchange
  • SSII Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • SSII 1.4B
  • ZYME 1.2B
  • IPO Year
  • SSII N/A
  • ZYME 2017
  • Fundamental
  • Price
  • SSII $6.89
  • ZYME $18.01
  • Analyst Decision
  • SSII
  • ZYME Strong Buy
  • Analyst Count
  • SSII 0
  • ZYME 7
  • Target Price
  • SSII N/A
  • ZYME $22.00
  • AVG Volume (30 Days)
  • SSII 142.8K
  • ZYME 960.4K
  • Earning Date
  • SSII 10-28-2025
  • ZYME 11-06-2025
  • Dividend Yield
  • SSII N/A
  • ZYME N/A
  • EPS Growth
  • SSII N/A
  • ZYME N/A
  • EPS
  • SSII N/A
  • ZYME N/A
  • Revenue
  • SSII $36,066,457.00
  • ZYME $134,481,000.00
  • Revenue This Year
  • SSII N/A
  • ZYME $99.52
  • Revenue Next Year
  • SSII N/A
  • ZYME N/A
  • P/E Ratio
  • SSII N/A
  • ZYME N/A
  • Revenue Growth
  • SSII 158.36
  • ZYME 116.21
  • 52 Week Low
  • SSII $2.48
  • ZYME $9.03
  • 52 Week High
  • SSII $22.42
  • ZYME $19.98
  • Technical
  • Relative Strength Index (RSI)
  • SSII 40.73
  • ZYME 52.07
  • Support Level
  • SSII $6.15
  • ZYME $16.00
  • Resistance Level
  • SSII $7.77
  • ZYME $19.98
  • Average True Range (ATR)
  • SSII 0.70
  • ZYME 0.84
  • MACD
  • SSII -0.30
  • ZYME -0.23
  • Stochastic Oscillator
  • SSII 22.27
  • ZYME 51.72

About SSII SS Innovations International Inc.

SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: